Argentine hemorrhagic fever

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:319223A96.0
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Argentine hemorrhagic fever (AHF), also known as Junín virus disease or O'Higgins disease, is a serious viral illness caused by the Junín virus, a type of arenavirus. The disease mainly affects people living or working in agricultural areas of the Argentine Pampas region, particularly during the harvest season from March to October. The virus is carried by a type of field mouse called Calomys musculinus, and people become infected by breathing in dust contaminated with the rodent's urine, saliva, or droppings, or through direct contact with infected rodents. The disease affects multiple body systems, especially the blood vessels and immune system. It typically begins with flu-like symptoms such as fever, headache, muscle pain, and fatigue. As the illness progresses, it can cause bleeding from the gums, nose, and other areas, along with neurological problems like tremors and confusion. In severe cases, it can lead to shock and organ failure. The most important treatment is immune plasma therapy, which involves giving patients blood plasma from people who have recovered from the disease. When given early in the illness, this treatment significantly reduces the death rate from around 15-30% to about 1%. A live attenuated vaccine called Candid #1 has been developed and is used in Argentina to protect people at high risk, particularly agricultural workers in affected areas. Supportive care, including fluids and management of bleeding, is also an important part of treatment.

Also known as:

Key symptoms:

High feverSevere headacheMuscle and joint painFatigue and general weaknessNausea and vomitingBleeding from the gumsNosebleedsSkin bruising or tiny red spots on the skinSwollen or red face and neckTremors or shakingConfusion or irritabilitySensitivity to lightLow blood pressureSwollen lymph nodesBlood in urine or stool

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Argentine hemorrhagic fever.

View clinical trials →

No actively recruiting trials found for Argentine hemorrhagic fever at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Argentine hemorrhagic fever community →

No specialists are currently listed for Argentine hemorrhagic fever.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Argentine hemorrhagic fever.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Argentine hemorrhagic feverForum →

No community posts yet. Be the first to share your experience with Argentine hemorrhagic fever.

Start the conversation →

Latest news about Argentine hemorrhagic fever

No recent news articles for Argentine hemorrhagic fever.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How soon can I receive immune plasma treatment, and is it available at this facility?,What signs of worsening should I watch for that would require emergency care?,How long will recovery take, and when can I return to work or normal activities?,Is there a risk of spreading the infection to my family members?,Should my family members or coworkers be vaccinated with the Candid #1 vaccine?,What precautions should I take in the future to avoid getting infected again?,Are there any long-term complications I should be aware of after recovery?

Common questions about Argentine hemorrhagic fever

What is Argentine hemorrhagic fever?

Argentine hemorrhagic fever (AHF), also known as Junín virus disease or O'Higgins disease, is a serious viral illness caused by the Junín virus, a type of arenavirus. The disease mainly affects people living or working in agricultural areas of the Argentine Pampas region, particularly during the harvest season from March to October. The virus is carried by a type of field mouse called Calomys musculinus, and people become infected by breathing in dust contaminated with the rodent's urine, saliva, or droppings, or through direct contact with infected rodents. The disease affects multiple body

How is Argentine hemorrhagic fever inherited?

Argentine hemorrhagic fever follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Argentine hemorrhagic fever typically begin?

Typical onset of Argentine hemorrhagic fever is adult. Age of onset can vary across affected individuals.